Page 52 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $10.62
52wk Low $2.65 XORTX Therapeutics Inc. XRTX $4.65
3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1

(USD - in millions) www.xortx.com
Market Cap 13.4
Enterprise 8.8
Basic Shares Out. 2.90 COMPANY OVERVIEW
Float 2.63
Institutional Holdings 99.11% Detailed Analysis:Channelchek.com
Short Interest N/A
Avg. 90-Day Volume 0.02 XORTX is a pharmaceutical company with two clinically advanced
products in development: 1) our lead, XRx-008 program for ADPKD;
and 2) our secondary program in XRx-101 for acute kidney and other
acute organ injury associated with Coronavirus / COVID-19 infection. In
EPS Data addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic
Nephropathy. XORTX is working to advance its clinical development
2021 2022 2023 stage products that target aberrant purine metabolism and xanthine
CQ1 N/A (2.52) (0.95) oxidase to decrease or inhibit production of uric acid. At XORTX, we
CQ2 N/A (2.33) (0.85) are dedicated to developing medications to improve the quality of life
and future health of patients.
CQ3 N/A N/A N/A
CQ4 (1.63) (6.58) (0.47)
CY (3.34) (8.95) (2.92) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 2.32
ROE (ttm) -37.08
Debt-to-Total Cap. (mrq) 0.25
Fiscal Year End 31-Dec

3710 – 33rd S Alberta Beach AB T2L 2M1

Key Executives
CEO: Davidoff, Allen
CFO: Fairbairn, James
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures